resTORbio, Inc.
https://www.restorbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From resTORbio, Inc.
Who Wants To Live Forever? Forging A Regulatory Pathway For Longevity Drugs
Despite the growing interest, both in and outside of the biotech space, in the so-called ‘longevity’ industry, no regulatory pathway exists to market a drug with a purely geroprotective indication.
Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Cash-Rich PureTech Displays Resilience In Troubled Times
PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice